Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Share-based Compensation (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Share-based Compensation for 10 consecutive years, with $19.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 82.51% to $19.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.8 million through Dec 2025, up 68.38% year-over-year, with the annual reading at $66.8 million for FY2025, 68.38% up from the prior year.
  • Share-based Compensation for Q4 2025 was $19.3 million at Rhythm Pharmaceuticals, up from $18.8 million in the prior quarter.
  • The five-year high for Share-based Compensation was $19.3 million in Q4 2025, with the low at $4.6 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $9.0 million, with a median of $8.2 million recorded in 2023.
  • The sharpest move saw Share-based Compensation fell 11.17% in 2022, then surged 82.51% in 2025.
  • Over 5 years, Share-based Compensation stood at $4.7 million in 2021, then rose by 13.07% to $5.3 million in 2022, then skyrocketed by 64.06% to $8.7 million in 2023, then rose by 21.7% to $10.6 million in 2024, then soared by 82.51% to $19.3 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $19.3 million, $18.8 million, and $15.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.